- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI finds new home for stock
Molecular Biosystems shifted its stock exchange this month after being delisted from the NYSE. The company received notice in September that the NYSE had revised its listing criteria, requiring companies to have total market capitalization and
Molecular Biosystems shifted its stock exchange this month after being delisted from the NYSE. The company received notice in September that the NYSE had revised its listing criteria, requiring companies to have total market capitalization and stockholders equity of not less than $50 million. MBI was unable to meet this requirement, and was delisted on Jan. 4. The company began trading under the new symbol MBIO on NASDs (National Association of Securities Dealers) over-the-counter bulletin board on Jan. 5.
In November, San Diego-based MBI and Palatin Technologies of Princeton, NJ, signed an intent to merge (SCAN 11/24/99). The two firms are in discussions with the Securities and Exchange Commission and their stockholders, and hope to close the deal by April, according to Patricia Sullivan, spokesperson for MBI. If the merger is completed, the new firm will operate under Palatins name and will trade on AMEX.
In other MBI news, the company announced last month that Chugai Pharmaceuticals of Tokyo has paid MBI $2 million as Chugai starts clinical trials with Optison for assessment of left ventricular opacification and myocardial perfusion.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
